TP-271
- A fully synthetic tetracycline antibiotic in phase 1 clinical testing
- Development program targets respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens
- Potent activity in vitro against Gram-negative and Gram-positive pathogens associated with respiratory tract infections
- National Institutes of Health’s National Institute of Allergy and Infectious Diseases funded preclinical development and phase 1 study
- Granted Qualified Infectious Disease Product and Fast Track designations by the U.S. Food and Drug Administration for both IV and oral formulations
- Positive safety and pharmacokinetic data from IV single-ascending and multiple-ascending dose studies
TP-6076
- A fully synthetic tetracycline antibiotic in phase 1 clinical development
- Potent activity in vitro against multidrug-resistant Gram-negative pathogens
- Phase 1 multiple-ascending dose study complete
- Received $4 million in funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to support development
Please contact us to learn more.